PATIENT PERCEPTION OF TREATMENT WITH LONG-TERM DUPILUMAB MONOTHERAPY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

被引：0
|
作者：
Simpson, E.
Lacour, J.
Beck, L.
Zhang, H.
Aamodt, K.
Rossi, A.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2021年 / 127卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P196
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [31] Long-term Dupilumab treatment up to 100 weeks reduces serum biomarkers in patients with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Bissonette, Robert
    Deleuran, Mette
    Harel, Sivan
    McDonald, Robert
    Shumel, Brad
    Rossi, Ana B.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 168 - 168
  • [32] Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis
    Achten, Roselie
    Bakker, Daphne
    Ariens, Lieneke
    Lans, Amanda
    Thijs, Judith
    Van der Schaft, Jorien
    De Boer, Joke
    Balak, Deepak
    De Graaf, Marlies
    Van Luijk, Chantal
    De Bruin-Weller, Marjolein
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (03): : 1389 - +
  • [33] Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
    Blauvelt, Andrew
    Hong, H. Chih-ho
    Peris, Ketty
    Katoh, Norito
    Tauber, Marie
    Ameen, Mahreen
    Gooderham, Melinda
    Oland, Christian Bjerregard
    Tindberg, Ann-Marie
    Gjerum, Le
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 30 - 31
  • [34] Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China
    Shi, Yin
    Zhou, Yanwu
    Li, Shuishi
    Guan, Haijing
    Liu, Shao
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1180 - 1189
  • [35] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
    Parker, Jennifer J.
    Sugarman, Jeffrey L.
    Silverberg, Nanette B.
    Gonzalez, Mercedes Elena
    Ramien, Michele L.
    Teng, Joyce M. C.
    Paller, Amy S.
    PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
  • [36] Treatment satisfaction in patients receiving dupilumab for moderate-to-severe atopic dermatitis
    Lans, A.
    Van der Schaft, J.
    Bakker, D.
    Ariens, L.
    Thijs, J. H.
    De Bruin-Weller, M. S.
    Balak, D. M. W.
    ALLERGY, 2019, 74 : 82 - 82
  • [37] Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    ALLERGY, 2020, 75 : 27 - 28
  • [38] Long-term dupilumab treatment up to 100 weeks has no impact on serum lipids in patients with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Bieber, T.
    Khokhar, F. A.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    ALLERGY, 2020, 75 : 192 - 193
  • [39] Dupilumab treatment provides long-term improvement in itch in pediatric patients with moderate-to-severe atopic dermatitis over 1 year
    Siegfried, Elaine
    Simpson, Eric L.
    Boguniewicz, Mark
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Pinter, Andreas
    Ramien, Michele
    Gao, Xing-Hua
    Chen, Zhen
    Bates, Lauren
    Rossi, Ana B.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II56 - II57
  • [40] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Bastian, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 55 - 56
12345